Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies

摘要: Aim Current guidelines recommend all patients scheduled to receive chemotherapy should be screened for hepatitis B surface antigen (HBsAg) and antibodies virus core (anti-HBc) status. However, still, more research is needed identify the risk factors (HBV) reactivation. We retrospectively investigated incidence, outcome of HBV reactivation in HBsAg negative with hematological malignancies. Methods Seven hundred thirty-eight malignancies were included study. was defined as reverse seroconversion (HBsAg reappearance). Risk factors, cumulative incidence overall survival analyzed. Results Reactivation occurred 23 738 (3.1%) enrolled patients. As expected, rate anti-HBc positive group significantly higher than that (5.4% vs 0.8%). Multivariate analysis indicated loss antibody (anti-HBs) an independent factor. Patients acute lymphoblastic leukemia multiple myeloma showed those other diseases. The after starting subgroup 0.3% at 1 year, 1.7% 2 years 10.5% 3 years. Conclusion Close monitoring markers, including anti-HBs, performed longer 24 months. Further study establish a strategy prevent malignancies.